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INTRODUCTION
Estrogen receptor (ER) status of breast tumor (expressed as + or – status) is a well-accepted predictor of response to endocrine therapy. In addition, a down-stream marker of functional 
ER signaling (1), progesterone receptor (PR), is measured in breast cancer (BC) biopsies and 
surgical samples. Now, it is known that two receptors for estrogen exist: ER? and ER?, encoded 
by two different genes: ER? is encoded by gene located on chromosomal loci 6q25.1 (2), and 
the ER??????????????????????????????????????????????????????????????????????????????????????
splice variants of both ER? and ER?, suggests that complex regulation of estrogen action exists. 
The exact biological significance of isoforms and its splice variants of both receptors (ER? and 
ER?), is still unclear, but it seems that their existence may have regulatory role in the response 
to estrogen. Both genes, ER? and ER?, have complex “system” of multiple promoters and 
differential splicing in 5’-UTR region (4). Exon deletions or duplications are second mechanism 
that potentially generates changes in reading frame, and, accordingly, exchanged proteins (5,6). 
In addition, five ER? isoforms (designated as ER?1 - ER?5) originate by alternative usage of five 
8th codons (7,8). It has been shown that the expression of ER? increases during the process of 
cancerogenesis, but the expression of ER? seems to decreases. Estrogen receptor ? is under 
intensive investigation and its role in BC appears to be of predictive value, too. It is reasonable 
to propose that ER status should now include both receptors, ER? and ER?.
In this study, we measure expression levels of mRNA of two ER? variants ER?1 and 
ER????? ??? ????? ??????? ???? ???????? ??????? ???? ???1 and ER???? ????? ??????????? ???
systematic sample of invasive BC. In addition, we compared ER? status with ER? and PR 
status. For this purpose, we quantified the expression levels of mRNA of two isoforms of 
ER? gene in 60 samples of primary operable BC samples and in adjacent normal tissue 
by the real-time RT-PCR. This study was performed by using the sensitive and sequence 
specific assays based on TaqMan methodology. Relative levels of ER?1 and ER????????????
were measured by assays designed to detect these transcript at unique regions.
MATERIAL AND METHODS
Patients 
We analyzed 60 samples obtained after surgery from patients with primary breast tumors, 
hospitalized at the Institute of Oncology and Radiology of Serbia in Belgrade. The study had 
received Institutional Review Board approval according to the National Health Regulation. 
Adjacent normal tissues are obtained after total mastectomy. Tissue was stored at liquid 
nitrogen until RNA and protein isolation. The patients all met the following criteria: primary 
operable unilateral invasive BC, without previous treatment. 
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ABSTRACT
Background: Estrogen and progesterone receptor (ER/PR) status is an accepted predictive marker 
in breast cancer. It is well known that breast tumors, which are ER(+) are more likely to respond to 
endocrine therapy. However, certain percentage of ER(+)/PR(+) tumors do not respond to endocrine 
therapy. Identification of the second estrogen receptor, named estrogen receptor beta (ER?), as well 
as the existence of numerous isoforms/splice variants of both ER? and ER?, suggests that complex 
regulation of estrogen action exists. In this study, we analyze does the expression of two ER? isoforms 
correlates with ER?/PR status.
Methods: Sixty samples of primary operable breast carcinomas were analyzed for ER? and PR protein 
levels and for mRNA expression of two ER? isoforms (ER?1 and ER????????? and PR proteins were 
measured by classical biochemical techniques, and ER? mRNAs were measured by real-time RT-PCR. 
Results: Tumors are divided in three groups according to relative level of mRNA for ER?1 and ER?????
We found that there is no correlation of ER?1 mRNA expression with ER? and PR protein levels. We 
confirmed the existence of inverse correlation of ER????????????????????????????????? in the group of 
postmenopausal patients. In the subsets of tumors defined by ER?/PR status, we found that percentage 
of tumors, which concomitantly expressed high levels of both transcripts, are parallel with those that do 
not response to tamoxifen treatment.
Conclusion: Inverse correlation of ER? with ER??????????????????????????????????????????????????
may have inhibitory effect on ER? activity in postmenopausal patients. In addition, we point out that 
determination of expression profiles of ER? and ER? isoforms in the defined groups of patient are nec-
essary for elucidating its involvement in endocrine resistance.
KEY WORDS: Breast Neoplasms; Receptors, Estrogen; Receptors, Progesterone; Antineoplastic Agents, 
Hormonal; Reverse Transcriptase Polymerase Chain Reaction
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Steroid receptor assay 
Steroid receptors, ER? and PR were measured by a five-point dextrane-coated charcoal 
assay in a cytosol fraction of frozen tumor tissue as previously described (9). 
RNA Isolation and cDNA synthesis 
The approximately 50–100 mg of tissue frozen in liquid nitrogen was pulverized in cold 
mortar vessel and extraction of total RNA was performed with acid-phenol guanidine 
method (10). Quality of RNA preparation was verified on agarose gels stained with ethidium 
bromide. RNA was dissolved again and concentration was determined spectrophotometri-
cally. Total RNA (1µg) was reverse transcribed in 20µl reaction volume with Omniscript 
RT Kit (Qiagen, Hilden, Germany) using the 10µM random hexamer and 1µM oligodT(15) 
primer according to manufacturer conditions (reverse transcription was performed 60 min 
??????????
Real-time PCR analysis 
All PCR reactions were performed using a 7000 Sequence Detection System (Applied 
Biosystems). PCR was carried out in 25 µl reaction volume containing the 1x TaqMan 
Universal PCR Master Mix (Applied Biosystems), 1x TaqMan Pre-Designed Gene Expression 
Assay specific for target transcript sequence and cDNA diluted with water (1:10). Relative 
quantity of target transcripts ER?1 or ER?????????????????????????????????????????????????-
ferences relative to calibrator, or 1x sample, according to equation: N = 2?????????????? ?????????????.
???????????????????????????????????????????????????????????????????????????????????????????
target transcripts (ER?1 and ER???????????????????????????????????-actin gene (endogenous 
control) (11). 
Statistical analysis 
Since levels of expression show non-Gaussian distribution, nonparametric tests (Spearman, 
Mann- Whitney and Chi square) were used for the analysis of correlation with clinical and 
histopathological parameters.
RESULTS
Relative quantities of ER?1 and ER????????????????????????????????????????????????????-
tion to calibrator and normalized to the ? actin as a reference gene. Distributions of RNA 
expression levels for both transcripts were the same as distribution of ER? and PR proteins 
and according to Kolmogorov-Smirnov test, values vary significantly from the pattern of a 
normal distribution.
Expression of ER?1 and ER?????????????????????????????????
breast tissue
Concerned with fact that there are no cut-off values for ER? expression of mRNA level, and 
??????????????????????????????????????????????????????????????????????????????????????????????
In this study we classified the BC samples according to expression of ER?1 and ER????
mRNA as “low expressed” (Tu1), “medium expressed” (Tu2), and “high expressed” (Tu3). 
Samples with “high expression” (Tu3) of ER?1 were defined as those in which more than 
three fold differences (in respect to calibrator) were detected; “medium expression” (Tu2) 
were those between one to three fold differences, and “low expression” (Tu1) were those 
with less than one fold difference. In the same way, the expression level is defined for 
the ER????????????????????????????????????????????????????????????????????????????????????
difference; Tu2 between two and six fold difference, and Tu1 less than two fold difference. 
This classification and numbers of samples in each expression group were showed in Table 
1. Expression levels of ER?1 and ER????????? ??? ?????? ?????????????????????????????
compared with expression level in healthy mammary tissue (N), Table 1. Samples in “high 
expression” group (Tu3) does not differ significantly from the expression level in healthy 
mammary tissue (Tu3 vs. N, Mann-Whitney for ?1, p=0.315, Figure 1; Tu3 vs. ER?????
Mann-Whitney for ????????????????????????????????????????????????????????????????????
and in “low expression” group (Tu1) significantly vary from the expression level in healthy 
mammary tissue. For ER?1 Tu2 group vs. N, p=0.023, and Tu1 group vs. N, p=0.001 
(Mann-Whitney), Figure 1. For ER????????????????????????????????????????????????????
(Mann-Whitney). Expression between ”low expression” and “medium expression” groups 
does not differ significantly neither for ER?1, nor for ER????
It is apparently that Tu3 tumors (those do not differ from expression level in normal tissue) 
could be considered as ”positive” for ER? expression, and Tu2 and Tu1 could be considered 
as ”negative” for ER? expression. 
Table 1. Expression of ER?1 and ER???????????????????????????????????????????????????????
Number of samples Mean* Median* Range*
ER?1
Breast cancer tissue
(+) High expressed (T3) (34) 12,340 6,928 3,091-70,427
(-)
medium expressed (Tu2) (14) 2,060 2,035 1,124-2,966
low expressed (Tu1) (12) 0,523 0,581 0,000-1,000
Healthy mammary tissue (N) 50,208 23,154 0,989-205,372
ER???
Breast cancer tissue
(+) High expressed (Tu3) (26) 21,074 9,962 6,272-102,508
(-)
medium expressed (Tu2) (25) 3,584 3,203 2,132-5,831
low expressed (Tu) (9) 1,108 1,007 0,000-1,754
Healthy mammary tissue (N) 108,811 48,694 2,662-358,389
*All values are expressed in relative expression level (n-fold difference in respect to 
calibrator) and obtained from 100 ng of total RNA.
Figure 1. Three groups of breast cancers according to expression of ER?1 isoform mRNA (Tu1, Tu2 
and Tu3) compared with healthy mammary tissue (N)
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Figure 2. Three groups of breast cancers according to expression of ER???????????????????????????
and Tu3) compared with healthy mammary tissue (N)
Correlation of ER?1 and ER???????????????????????????????????????
ER? and PR
We examined does the expression status of ER?1 and ER?????????? ??????????? ?????
ER?????????????????????????????????????????????????????????????????????????????????????
cytosol proteins) and 24 were ER?-negative. According to PR status, 20 samples were 
??????????????????????????????????????????????????????????????????????????????
Analysis of association between ER? and PR protein levels shows no correlation with 
expression of the wild type of estrogen receptor beta (ER?1).
We found correlation between ER????????? ???? ??? ???????? ??? ???? ????????? ??? ????-
menopausal patients (ER???????????????? ???????? ???????????????????? ??? ????? ?????????
patients significant inverse correlation exist between ER???????????????? (Spearman,
?=-0.335, p=0.04). There is no correlation between ER???????????????? or PR in the 
group of premenopausal patients (results not shown). 
In order to examine does the ER? expression correlates with established percentage of endo-
crine unresponsive patients, we analyze expression of both ER? transcripts in groups defined 
by the ER ER????????????????????????????????????????????????????????????????????????????
??????????? ?????? ??? ????? ????????????? ??? ???? ??????? ??? ????????????????????????? ???????-
??????????????????????????????????????????????????????????????????????????? ??????????????
Assignment of the tumors with high expression of ER?1 and ER??????????????????????? ??-
tioned groups of patients are parallel to the percentage of endocrine unresponsive ones. 
DISCUSSION
Majority of available data about ER? expression in clinical samples come from the immuno-
histochemical studies. Quantification of ER? expression on RNA level is justified, since the 
ER? mRNA increases in parallel with the increase in protein level as showed by Cheng et al 
(12), indicating that regulation of ER? expression is on transcriptional level. 
In this study, we performed the specific and sensitive TaqMan pre-designed assay for qPCR to 
quantify mRNA of ER?1 (wt isoform) and ER??????????????????????????????????????????????????
of ER?2 isoform. ER?????????????????????????????????????????????????????????????????
In examined samples of BC we found that there are two groups, according to expression 
of ER?1 and ER????? i) those that are not different compared to normal mammary tissue 
(referred as ER?-positive or “high expressed” (Tu3)), Table 1, Figure 1 and 2.; ii) and those in 
which expression levels significantly varies from normal mammary tissue (referred as ER?-
negative or “medium expressed” (Tu2) and “low expressed” (Tu1)), Table 1, Figure 1 and 2.
We found no correlation between expression of ER?1 mRNA, measured by qRT-PCR and 
ER? measured by ligand binding assay. Other authors also report (in immunohistochemi-
cal studies) that there is no correlation between ER? and ER? expression on protein level 
(13,14). The absence of correlation of ER?1 expression with clinical and histopathological 
parameters (our unpublished results), indicate that its expression level could be an indepen-
dent predictive marker in BC, but its predictive value remains to be established. 
Interestingly, little is known about expression of ER??????????????????????????????????????????
fifth exon results in frame shift in reading frame of protein, generating five alternative amino 
acids, and stop codon after them, which results in truncated protein without ligand bind-
ing domain. In cell transfection studies (16), it was shown that ER??????????????????????
possesses dose dependent, inhibitory activity against and ER? in 293T cell line. A similar 
activity, also in eukaryotic cell culture system, has its counterpart, ER????????????????????
the ER? on ERE reporter genes. 
Our finding of inverse correlation of ER???????????????????????? in postmenopausal patients 
are in concordance with in vitro study of Inoue and coworkers (16) and may reflect the inhibi-
tory activity of this truncated protein in vivo against transcriptional activity of ER? receptor. 
Inverse correlation of PR and ER?2 was also reported by Saji and coworkers (17). Their data, 
together with our result that ER???????????????????????????????????????in vivo suggest that high 
expression of some ER? isoforms may underlie the emergence of ER???????????????????????
cells. Inverse association between expression of ER?????????????????????????????????????????
be the consequence of inhibition of estrogen-induced activity of ER? by hetero-dimerization 
with truncated protein encoded by ??????????????????????????????????????????????????????????
that this inverse correlation comes from postmenopausal subset of patients, points out that this 
inhibitory activity might be detectable in vivo only when levels of circulating estrogen is low.
????????????? ????????????????????????????????????????????????????????????????????????????????
of concomitantly “highly expressed” ER?1 and ER????????????????????????????????????????-
centages of endocrine unresponsive patients. Poola and coworkers (15) recently published 
similar results where they show that two isoforms of ER? receptor (?1 and ?5) are highly 
expressed in ER?-negative tumors. Biochemical explanation for this occurrence is that in 
the absence of ER? the ER? can be mediator of estrogen signaling as suggested by Poola 
(15). Moreover, there are data that tamoxifen may have agonistic effect on ER? in HeLa 
cells and BC cell lines. At the same time, high level of ER???????????? ????????? ???????
with ER? (16)) may suppress the ER? activity. Although it is widely documented that the 
decreased expression of ER? correlates with tumor emergence and progression, the role of 
this receptor in tamoxifen resistance remains unclear.
Our approach in defining of ER? mRNA positive and negative is based on comparison 
between normal and malignant tissue is justified, since we obtained results comparable 
with data obtained in immunohistochemical studies. This approach may be helpful in future 
studies dealing with clinical significance of ER?.
In conclusion, we point out the necessity for analyzing the complete isoform profiles of ER?,
ER? and PR in clinical samples, since it is possible that one pattern of isoforms expression 
may be a cause of tamoxifen resistance and the other might be a marker of sensitivity.
Note
This work was supported by the Serbian Ministry of Science and Environmental Protection 
(Grant 143010 and Grant 145018).
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